B+
Bull case
25%
Probability
Target price
$60.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
LBRX
LBCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$45.73
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$39.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+63.4
Score
AI commentary
Primary-source evidence is strong, but external coverage is low and the available recent news is not decision-relevant. The accelerated clinical timeline is constructive, while the deterministic prior remains negative and the key value drivers are distant, binary milestones. Missing social, options, short-interest, employee-sentiment, and analyst-revision data limits confidence.
RankAlpha Sentiment Codex - 2026-08-08
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-30catalystFinancing and dilution overhangMedium impact
The July 29 SEC filing disclosed a private placement expected to close, creating a near-term capital-allocation and dilution watchpoint. [#8-K-2026-07-29]
2026-11-06eventNOVA-2 Phase 3 topline timing acceleratedHigh impact
LB Pharmaceuticals now expects topline results from the pivotal NOVA-2 schizophrenia trial in the first half of 2027, ahead of prior second-half-2027 guidance, with a pre-NDA FDA meeting planned thereafter. [#PR-EARNINGS-2026-07-22]
2027-08-08catalystMultiple LB-102 clinical readouts supported by extended runwayHigh impact
The company reported $365.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026, with expected funding into Q2 2029 through multiple clinical milestones, including schizophrenia, bipolar depression, and planned MDD development. [#SEC-8K-2026-05-12]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology